Smoking and Nicotine Use Among Youths Seen at a Tertiary Care Rheumatology Practice
IRB Number: 2025-0570
December 16, 2025
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
Summary of Study Intervention
Hope to enroll 400 patients; enrollment between December 2025-spring 2026; no follow up.
Patients evaluated by a pediatric rheumatologist outside of Hospital for Special Surgery in the last 5 years for any rheumatic condition will be sent one electronic survey to assess their exposure to smoking/vaping and nicotine use. We are interested in the opinions of all these patients, not just those who use these products. Patients who are under 18 years of age must get their parent to provide consent to participate. This survey should take less than 20 minutes to complete; duration will vary based on their answer choices.
Inclusion/Exclusion Criteria:
Inclusion Criteria: youths ages 15-22 years old who have been evaluated by a pediatric rheumatologist outside of Hospital for Special Surgery (HSS) in the last 5 years (2021-2025)
Exclusion Criteria: youths not in this age group; youths evaluated at HSS
Contact Information for the Study:
Patricia Hoffman
917-890-7857